SK3972002A3 - Antibody dye conjugates and pharmaceutical composition containing the same - Google Patents

Antibody dye conjugates and pharmaceutical composition containing the same Download PDF

Info

Publication number: SK3972002A3
Authority: SK; Slovakia
Prior art keywords: dye; antibody; dyes; disease; group
Prior art date: 1999-09-24

Application number

SK397-2002A

Other languages

English (en)

Slovak (sk)

Inventor

Michael Schirner

Kai Licha

Ludger Dinkelborg

Original Assignee

Schering Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-24

Filing date

2000-08-19

Publication date

2002-09-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7924318&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK3972002(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-08-19 Application filed by Schering Ag filed Critical Schering Ag

2002-09-10 Publication of SK3972002A3 publication Critical patent/SK3972002A3/sk

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 8
201000010099 disease Diseases 0.000 claims abstract description 43
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 43
230000003287 optical effect Effects 0.000 claims abstract description 6
239000000975 dye Substances 0.000 claims description 154
238000001356 surgical procedure Methods 0.000 claims description 26
230000002093 peripheral effect Effects 0.000 claims description 22
238000003384 imaging method Methods 0.000 claims description 15
230000033115 angiogenesis Effects 0.000 claims description 12
ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 claims description 10
239000000203 mixture Substances 0.000 claims description 8
201000011510 cancer Diseases 0.000 claims description 7
230000003595 spectral effect Effects 0.000 claims description 7
125000004432 carbon atom Chemical group C* 0.000 claims description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
125000004430 oxygen atom Chemical group O* 0.000 claims description 6
206010027476 Metastases Diseases 0.000 claims description 5
QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 5
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
229960003330 pentetic acid Drugs 0.000 claims description 5
102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
125000000217 alkyl group Chemical group 0.000 claims description 4
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
150000001875 compounds Chemical class 0.000 claims description 4
DZVCFNFOPIZQKX-LTHRDKTGSA-M merocyanine Chemical compound [Na+].O=C1N(CCCC)C(=O)N(CCCC)C(=O)C1=C\C=C\C=C/1N(CCCS([O-])(=O)=O)C2=CC=CC=C2O\1 DZVCFNFOPIZQKX-LTHRDKTGSA-M 0.000 claims description 4
229920006395 saturated elastomer Polymers 0.000 claims description 4
BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 claims description 3
201000009273 Endometriosis Diseases 0.000 claims description 3
239000000872 buffer Substances 0.000 claims description 3
239000000969 carrier Substances 0.000 claims description 3
201000003511 ectopic pregnancy Diseases 0.000 claims description 3
229960001483 eosin Drugs 0.000 claims description 3
SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 claims description 3
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 3
201000011066 hemangioma Diseases 0.000 claims description 3
229910052739 hydrogen Inorganic materials 0.000 claims description 3
229910052760 oxygen Inorganic materials 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 3
125000004964 sulfoalkyl group Chemical group 0.000 claims description 3
229910052717 sulfur Inorganic materials 0.000 claims description 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
150000000918 Europium Chemical class 0.000 claims description 2
229910052771 Terbium Inorganic materials 0.000 claims description 2
125000003118 aryl group Chemical group 0.000 claims description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
239000000298 carbocyanine Substances 0.000 claims description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
125000005647 linker group Chemical group 0.000 claims description 2
239000001301 oxygen Substances 0.000 claims description 2
QWYZFXLSWMXLDM-UHFFFAOYSA-M pinacyanol iodide Chemical compound [I-].C1=CC2=CC=CC=C2N(CC)C1=CC=CC1=CC=C(C=CC=C2)C2=[N+]1CC QWYZFXLSWMXLDM-UHFFFAOYSA-M 0.000 claims description 2
239000001022 rhodamine dye Substances 0.000 claims description 2
239000002904 solvent Substances 0.000 claims description 2
125000005504 styryl group Chemical group 0.000 claims description 2
GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 claims description 2
RRBYUSWBLVXTQN-UHFFFAOYSA-N tricyclene Chemical compound C12CC3CC2C1(C)C3(C)C RRBYUSWBLVXTQN-UHFFFAOYSA-N 0.000 claims description 2
RRBYUSWBLVXTQN-VZCHMASFSA-N tricyclene Natural products C([C@@H]12)C3C[C@H]1C2(C)C3(C)C RRBYUSWBLVXTQN-VZCHMASFSA-N 0.000 claims description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
125000004429 atom Chemical group 0.000 claims 1
125000000332 coumarinyl group Chemical class O1C(=O)C(=CC2=CC=CC=C12)* 0.000 claims 1
239000011593 sulfur Substances 0.000 claims 1
230000000694 effects Effects 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
210000001519 tissue Anatomy 0.000 description 31
206010028980 Neoplasm Diseases 0.000 description 28
238000000034 method Methods 0.000 description 10
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
230000008569 process Effects 0.000 description 6
-1 4-sulfobutyl Chemical group 0.000 description 5
238000009825 accumulation Methods 0.000 description 5
230000008901 benefit Effects 0.000 description 5
210000004204 blood vessel Anatomy 0.000 description 5
230000005855 radiation Effects 0.000 description 5
239000000243 solution Substances 0.000 description 5
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
238000001514 detection method Methods 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
241000699660 Mus musculus Species 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
239000003814 drug Substances 0.000 description 3
210000002889 endothelial cell Anatomy 0.000 description 3
230000005284 excitation Effects 0.000 description 3
238000011580 nude mouse model Methods 0.000 description 3
230000035515 penetration Effects 0.000 description 3
108010033574 phasin Proteins 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
239000007787 solid Substances 0.000 description 3
230000002792 vascular Effects 0.000 description 3
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
108060003393 Granulin Proteins 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
239000002870 angiogenesis inducing agent Substances 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
NYPJDWWKZLNGGM-UHFFFAOYSA-N fenvalerate Chemical compound C=1C=C(Cl)C=CC=1C(C(C)C)C(=O)OC(C#N)C(C=1)=CC=CC=1OC1=CC=CC=C1 NYPJDWWKZLNGGM-UHFFFAOYSA-N 0.000 description 2
239000007850 fluorescent dye Substances 0.000 description 2
238000012632 fluorescent imaging Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 2
239000007788 liquid Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000011546 protein dye Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical class C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
MHIITNFQDPFSES-UHFFFAOYSA-N 25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1(25),2,4,6,8(27),9,11,13,15,17,19,21,23-tridecaene Chemical compound N1C(C=C2C3=CC=CC=C3C(C=C3NC(=C4)C=C3)=N2)=CC=C1C=C1C=CC4=N1 MHIITNFQDPFSES-UHFFFAOYSA-N 0.000 description 1
ACNUVXZPCIABEX-UHFFFAOYSA-N 3',6'-diaminospiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(N)C=C1OC1=CC(N)=CC=C21 ACNUVXZPCIABEX-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
229910052693 Europium Inorganic materials 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
102000016359 Fibronectins Human genes 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
102000009465 Growth Factor Receptors Human genes 0.000 description 1
108010009202 Growth Factor Receptors Proteins 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
208000034038 Pathologic Neovascularization Diseases 0.000 description 1
206010035148 Plague Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
241000607479 Yersinia pestis Species 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
230000004913 activation Effects 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
230000002491 angiogenic effect Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
229960000956 coumarin Drugs 0.000 description 1
235000001671 coumarin Nutrition 0.000 description 1
GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical compound C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 description 1
150000004775 coumarins Chemical class 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
238000004163 cytometry Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
210000001723 extracellular space Anatomy 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
238000001917 fluorescence detection Methods 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
238000010562 histological examination Methods 0.000 description 1
230000001146 hypoxic effect Effects 0.000 description 1
230000001678 irradiating effect Effects 0.000 description 1
ZBKFYXZXZJPWNQ-UHFFFAOYSA-N isothiocyanate group Chemical group [N-]=C=S ZBKFYXZXZJPWNQ-UHFFFAOYSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000003902 lesion Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
229910052753 mercury Inorganic materials 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
229960002378 oftasceine Drugs 0.000 description 1
108010067933 oncofetal fibronectin Proteins 0.000 description 1
238000012634 optical imaging Methods 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
239000001007 phthalocyanine dye Substances 0.000 description 1
229920001515 polyalkylene glycol Polymers 0.000 description 1
150000004032 porphyrins Chemical class 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000009877 rendering Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000007974 sodium acetate buffer Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000000758 substrate Substances 0.000 description 1
125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
230000006444 vascular growth Effects 0.000 description 1
206010055031 vascular neoplasm Diseases 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
229910052724 xenon Inorganic materials 0.000 description 1
FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0039—Coumarin dyes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo

Landscapes

Health & Medical Sciences (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

SK397-2002A 1999-09-24 2000-08-19 Antibody dye conjugates and pharmaceutical composition containing the same SK3972002A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19947559A DE19947559A1 (de)	1999-09-24	1999-09-24	Antikörper-Farbstoffkonjugate gegen Zielstrukturen der Angiogenese zur intraoperativen Tumorranddarstellung
PCT/EP2000/008121 WO2001023005A1 (fr)	1999-09-24	2000-08-19	Conjugues anticorps-colorant contre des structures cibles de l'angiogenese pour une representation peroperatoire de bord de tumeur

Publications (1)

Publication Number	Publication Date
SK3972002A3 true SK3972002A3 (en)	2002-09-10

Family

ID=7924318

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK397-2002A SK3972002A3 (en)	1999-09-24	2000-08-19	Antibody dye conjugates and pharmaceutical composition containing the same

Country Status (22)

Country	Link
EP (2)	EP1532988A3 (fr)
JP (1)	JP2003510294A (fr)
KR (2)	KR20070087232A (fr)
CN (1)	CN1269530C (fr)
AU (1)	AU779026B2 (fr)
BG (1)	BG65682B1 (fr)
BR (1)	BR0014192A (fr)
CA (1)	CA2385593A1 (fr)
CZ (1)	CZ2002991A3 (fr)
DE (1)	DE19947559A1 (fr)
EE (1)	EE05176B1 (fr)
HU (1)	HUP0202625A2 (fr)
IL (2)	IL148405A0 (fr)
MX (1)	MXPA02002639A (fr)
NO (1)	NO20021441L (fr)
NZ (1)	NZ517944A (fr)
RO (1)	RO121598B1 (fr)
RU (1)	RU2002109237A (fr)
SK (1)	SK3972002A3 (fr)
WO (1)	WO2001023005A1 (fr)
YU (1)	YU20702A (fr)
ZA (1)	ZA200203225B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2003524018A (ja)	2000-02-24	2003-08-12	アイトゲネーシシェテクニシェホッホシューレチューリッヒ	フィブロネクチンのｅｄ‐ｂドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用
US6440389B1 (en) *	2000-07-19	2002-08-27	The General Hospital Corporation	Fluorescent agents for real-time measurement of organ function
AT413487B (de)	2002-08-12	2006-03-15	Igeneon Krebs Immuntherapie	Verwendung von antikörpern gegen ein tumor-assoziiertes antigen
NO20034351D0 (no) *	2003-09-29	2003-09-29	Amersham Health As	Optisk avbilding av endometrose
EP1619501B1 (fr) *	2004-07-22	2007-09-26	Bayer Schering Pharma Aktiengesellschaft	Utilisation des colorants cyanines dans le diagnostic des maladies associées à l'angiogénèse
EP1679082A1 (fr) *	2005-01-07	2006-07-12	Schering AG	Utilisation de colorants de type cyanine pour le diagnostic de maladies proliférantes
AU2010239272B2 (en) *	2009-04-21	2015-09-17	The University Of Utah Research Foundation	Light-emitting dye for intraoperative imaging or sentinel lymph node biopsy
WO2018026965A1 (fr) *	2016-08-02	2018-02-08	Isi Life Sciences, Inc.	Méthode de détection de cellules cancéreuses.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4341223A (en) *	1981-02-04	1982-07-27	Lutz Lauralee A	Fluoresceable composition and method of determining fluid flow
NZ288883A (en) *	1994-07-11	1998-12-23	Univ Texas	Conjugates comprising coagulation factors
TWI259837B (en) *	1998-05-11	2006-08-11	Eidgenossische Tech Hochscule	Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis

1999
- 1999-09-24 DE DE19947559A patent/DE19947559A1/de not_active Withdrawn
2000
- 2000-08-19 EE EEP200200152A patent/EE05176B1/xx not_active IP Right Cessation
- 2000-08-19 WO PCT/EP2000/008121 patent/WO2001023005A1/fr not_active Ceased
- 2000-08-19 CZ CZ2002991A patent/CZ2002991A3/cs unknown
- 2000-08-19 SK SK397-2002A patent/SK3972002A3/sk not_active Application Discontinuation
- 2000-08-19 HU HU0202625A patent/HUP0202625A2/hu unknown
- 2000-08-19 BR BR0014192-5A patent/BR0014192A/pt not_active Application Discontinuation
- 2000-08-19 KR KR1020077017452A patent/KR20070087232A/ko not_active Ceased
- 2000-08-19 RO ROA200200323A patent/RO121598B1/ro unknown
- 2000-08-19 CA CA002385593A patent/CA2385593A1/fr not_active Abandoned
- 2000-08-19 MX MXPA02002639A patent/MXPA02002639A/es not_active Application Discontinuation
- 2000-08-19 IL IL14840500A patent/IL148405A0/xx unknown
- 2000-08-19 AU AU67026/00A patent/AU779026B2/en not_active Ceased
- 2000-08-19 JP JP2001526214A patent/JP2003510294A/ja active Pending
- 2000-08-19 EP EP05075349A patent/EP1532988A3/fr not_active Withdrawn
- 2000-08-19 EP EP00954640A patent/EP1214099A1/fr not_active Withdrawn
- 2000-08-19 CN CNB00813295XA patent/CN1269530C/zh not_active Expired - Fee Related
- 2000-08-19 YU YU20702A patent/YU20702A/sh unknown
- 2000-08-19 KR KR1020027003738A patent/KR100832937B1/ko not_active Expired - Fee Related
- 2000-08-19 RU RU2002109237/14A patent/RU2002109237A/ru not_active Application Discontinuation
- 2000-08-19 NZ NZ517944A patent/NZ517944A/en unknown
2002
- 2002-02-27 IL IL148405A patent/IL148405A/en not_active IP Right Cessation
- 2002-03-19 BG BG106528A patent/BG65682B1/bg unknown
- 2002-03-22 NO NO20021441A patent/NO20021441L/no unknown
- 2002-04-23 ZA ZA200203225A patent/ZA200203225B/en unknown

Also Published As

Publication number	Publication date
KR20020039349A (ko)	2002-05-25
IL148405A (en)	2009-06-15
IL148405A0 (en)	2002-09-12
EE200200152A (et)	2003-04-15
AU6702600A (en)	2001-04-30
NZ517944A (en)	2004-06-25
BR0014192A (pt)	2002-05-21
EE05176B1 (et)	2009-06-15
ZA200203225B (en)	2003-07-23
MXPA02002639A (es)	2002-07-30
NO20021441L (no)	2002-05-15
DE19947559A1 (de)	2001-04-19
CZ2002991A3 (cs)	2002-06-12
KR20070087232A (ko)	2007-08-27
HUP0202625A2 (en)	2002-12-28
WO2001023005A1 (fr)	2001-04-05
HK1050491A1 (en)	2003-06-27
PL354027A1 (en)	2003-12-15
CN1376074A (zh)	2002-10-23
EP1214099A1 (fr)	2002-06-19
CN1269530C (zh)	2006-08-16
NO20021441D0 (no)	2002-03-22
RU2002109237A (ru)	2003-11-27
JP2003510294A (ja)	2003-03-18
BG106528A (bg)	2002-12-29
EP1532988A2 (fr)	2005-05-25
AU779026B2 (en)	2005-01-06
YU20702A (sh)	2005-06-10
EP1532988A3 (fr)	2008-09-17
KR100832937B1 (ko)	2008-05-27
CA2385593A1 (fr)	2001-04-05
BG65682B1 (bg)	2009-06-30
RO121598B1 (ro)	2007-12-28

Publication	Publication Date	Title
JP3836687B2 (ja)	2006-10-25	生体内診断剤に適する化合物
RU2350355C9 (ru)	2009-05-27	Флюоресцентный контрастирующий агент ближней инфракрасной области спектра и способ флуоресцентной томографии
DE60133626T2 (de)	2009-06-10	Hydrophile zyaninfarbstoffe
DE60106389T2 (de)	2006-03-09	Vielseitige hydrophile farbstoffe
JP2000095758A (ja)	2000-04-04	近赤外蛍光造影剤および蛍光造影方法
JP2010116413A (ja)	2010-05-27	近赤外線を用いた診断法および治療のための酸不安定性で酵素的に分割可能な染料構造体
US7947256B2 (en)	2011-05-24	Biocompatible fluorescent imaging agents
AU3373899A (en)	1999-10-25	Non-covalent bioconjugates useful for diagnosis and therapy
US6447749B1 (en)	2002-09-10	Perfluoro-alkyl containing dye molecules and galencial formulations
SK3972002A3 (en)	2002-09-10	Antibody dye conjugates and pharmaceutical composition containing the same
Krause	2002	Contrast Agents II: Optical, Ultrasound, X-Ray Imaging and Radiopharmaceutical Imaging
CN101272808A (zh)	2008-09-24	光学成像
JP3507060B2 (ja)	2004-03-15	近赤外蛍光造影剤及び蛍光イメージング
Li	2022	Structural Optimization of Heptamethine Cyanine Dyes
WO2005061456A1 (fr)	2005-07-07	Milieu de contraste fluorescent proche infrarouge
HK1050491B (zh)	2007-02-23	用於结合血管生成性靶组织以在手术中显影肿瘤边缘的抗体-染料结合物
TW202330498A (zh)	2023-08-01	用於腫瘤偵測及手術指引之化合物及組合物
CN114835629A (zh)	2022-08-02	一类咔唑苯并[cd]吲哚鎓盐及其制备方法与应用
PL203535B1 (pl)	2009-10-30	Koniugaty przeciwcia lo-barwnik, srodki farmaceutyczne je zawieraj ace i zastosowanie

Legal Events

Date	Code	Title	Description
2011-09-05	FC9A	Refused patent application